Resistance to Integrase Inhibitors

被引：83

作者：

Metifiot, Mathieu ^{[1
]}

Marchand, Christophe ^{[1
]}

Maddali, Kasthuraiah ^{[1
]}

Pommier, Yves ^{[1
]}

机构：

[1] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

VIRUSES-BASEL | 2010年 / 2卷 / 07期

关键词：

AIDS; HIV-1; integrase; Raltegravir; Elvitegravir; GSK-1349572; GSK-1265744; interfacial inhibitors; resistance; IMMUNODEFICIENCY-VIRUS TYPE-1; TREATMENT-NAIVE PATIENTS; LONG TERMINAL REPEAT; HIV-1; INTEGRASE; STRAND TRANSFER; ACTIVE-SITE; DIKETO ACID; RALTEGRAVIR RESISTANCE; CONCERTED INTEGRATION; RETROVIRAL INTEGRASE;

D O I：

10.3390/v2071347

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN coding sequence appear to confer cross-resistance. The characterization of those mutations is critical for the development of second generation IN inhibitors to overcome resistance. This review focuses on IN resistance based on structural and biochemical data, and on the role of the IN flexible loop i.e., between residues G140-G149 in drug action and resistance.

引用

页码：1347 / 1366

页数：20

共 50 条

[31] Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
Oliveira, Maureen
Mesplede, Thibault
Quashie, Peter K.
Moisi, Daniela
Wainberg, Mark A.
AIDS, 2014, 28 (06) : 813 - 819
[32] Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors
Goethals, O.
Clayton, R.
Wagemans, E.
Van Ginderen, M.
Vos, A.
Geluykens, P.
Dockx, K.
Smits, V.
Meersseman, G.
Jochmans, D.
Hallenberger, S.
Hertogs, K.
ANTIVIRAL THERAPY, 2008, 13 (04) : A11 - A11
[33] Novel integrase inhibitors for HIV
Prada, Nicole
Markowitz, Martin
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (09) : 1087 - 1098
[34] Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study
Cheung, Peter K.
Shahid, Aniqa
Dong, Winnie
Lepik, Katherine J.
Montaner, Julio S. G.
Brockman, Mark A.
Brumme, Zabrina L.
Brumme, Chanson J.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (04) : 979 - 988
[35] Will Integrase Inhibitors be Used as Microbicides?
Crucitti, Giuliana C.
Botta, Maurizio
Di Santo, Roberto
CURRENT HIV RESEARCH, 2012, 10 (01) : 36 - 41
[36] HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
Bar-Magen, Tamara
Donahue, Daniel A.
McDonough, Emily I.
Kuhl, Bjoern D.
Faltenbacher, Verena H.
Xu, Hongtao
Michaud, Veronique
Sloan, Richard D.
Wainberg, Mark A.
AIDS, 2010, 24 (14) : 2171 - 2179
[37] The clinical pharmacology of integrase inhibitors
Di Perri, Giovanni
Calcagno, Andrea
Trentalange, Alice
Bonora, Stefano
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (01) : 31 - 44
[38] Tolerability of HIV integrase inhibitors
Lee, Frederick J.
Carr, Andrew
CURRENT OPINION IN HIV AND AIDS, 2012, 7 (05) : 422 - 428
[39] Potential inhibitors of HIV integrase
Mathe', C
Nair, V
NUCLEOSIDES & NUCLEOTIDES, 1999, 18 (4-5): : 681 - 682
[40] Weight gain and integrase inhibitors
Eckard, Allison Ross
McComsey, Grace A.
CURRENT OPINION IN INFECTIOUS DISEASES, 2020, 33 (01) : 10 - 19

← 1 2 3 4 5 →